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Abstract
Background: Hypercalcemia is the most common oncologic metabolic emergency but very rarely observed in
patients with gastrointestinal stromal tumour, which is a rare mesenchymal malignancy of the gastrointestinal tract.
We describe a case of hypercalcemia caused by elevated levels of activated vitamin D in a patient with gastrointestinal
tumour. Prior to this case report, only one paper has reported an association between hypercalcemia, gastrointestinal
stromal tumours and elevated levels of vitamin D.
Case presentation: An otherwise healthy 70-year-old Caucasian woman, previously treated for duodenal
gastrointestinal stromal tumour, was diagnosed with liver metastasis, and relapse of gastrointestinal stromal
tumour was confirmed by biopsy. At presentation, the patient suffered from severe symptoms of hypercalcemia. The
most common causes of hypercalcemia, hyperparathyrodism, parathyroid hormone-related peptide secretion from
tumour cells, and metastatic bone disease, were all dismissed as the etiology. Analysis of vitamin D subtypes revealed
normal levels of both 25-OH Vitamin D2 and 25-OH Vitamin D3, whereas the level of activated vitamin D, 1,25 OH
Vitamin D3, also referred to as calcitriol, was elevated.
Conclusion: The fact that plasma calcitriol decreased after initiation of oncological treatment and the finding that
hypercalcemia did not recur during treatment support the conclusion that elevated calcitriol was a consequence
of the gastrointestinal stromal tumour. We suggest that gastrointestinal stromal tumours should be added to the
list of causes of humoral hypercalcemia in malignancy, and propose that gastrointestinal stromal tumour tissue
may have high activity of the specific enzyme 1α-hydroxylase, which can lead to increased levels of calcitriol and
secondarily hypercalcemia.
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Background
Hypercalcemia is the most common oncologic metabolic
emergency. Up to 30 % of all cancer patients will experi-
ence tumour-induced hypercalcemia (TIH) [1, 2]. The
most common reason is humoral hypercalcemia of
malignancy (HHM) which is caused by parathyroid
hormone-related peptide (PTHrP) secretion from tumour
cells (approximately 80 % of cases), followed by metastatic
bone disease (approximately 20 %). In a few percent of
cases, hypercalcemia is caused by tumour cells producing
1,25 OH-Vitamin D or parathyroid hormone (PTH) [1].
The malignancies most often associated with hypercalce-
mia are multiple myeloma, breast, lung, and renal cell car-
cinoma [1]. Patients suffering from gastrointestinal stromal
tumour (GIST) very rarely experience hypercalcemia [3].
GIST is a rare neoplasm but remains the most com-
mon mesenchymal tumour of the gastrointestinal tract,
with an incidence of 11–19.6 per million and a median
age of diagnosis around 65 years. Most often, the tumour
is localized at presentation, but up to half of the patients
will suffer from recurrence, which most frequently occurs
in the peritoneal cavity or in the liver. GIST is highly
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resistant to conventional chemotherapy, however, fol-
lowing the introduction of tyrosine kinase inhibitors, e.g.
imatinib, in both the preoperative, adjuvant and metastatic
setting the prognosis has dramatically improved [4].
Below, we present a case of hypercalcemia in a patient
with recurrent GIST disease.
Case presentation
On June 12 2014, a 70-year-old Caucasian woman was
referred to the fast track cancer referral programme at
Aarhus University Hospital, Denmark, due to a palpable
abdominal mass, a 4–5 kg weight loss, and fatigue. Six
years previously the patient had undergone a Whipple
operation where a 3.8 cm duodenal GIST tumour was
radically resected. After surgery the patient was followed
with regular CT scans for four and a half years. No adju-
vant treatment with imatinib was given, as this was not
standard of care for high risk patients in Denmark in
2008. After the cessation of her follow-up, the patient
had been well until her weight loss in spring 2014.
Initial routine biochemistry revealed elevated p-ionized
calcium; 2.11 mmol/L, suppressed p-PTH; 1.5 pmol/L,
and impaired renal function with an estimated glomerular
filtration rate (eGFR) of 37 mL/min, one year previously
eGFR was 88 mL/min. Finally, p-total alkaline phos-
phatase was slightly elevated to 148 U/L but other
routine biochemistry was normal. At the time of surgery
in 2008 p-total calcium was not elevated, and p-ionized
calcium was not measured.
To further characterize the cause of hypercalcemia,
plasma levels of monoclonal protein, calcitriol and PTHrP
were measured. Monoclonal protein and PTHrP were un-
detectable but calcitriol was more than twofold elevated
(375 pmol/L). See Table 1 for biochemistry.
A regular CT scan was followed by a PET-CT scan
and two hepatic tumours, measuring 11.0 × 8.6 cm
and 9.2 × 8.2 cm were found, but no bone lesions.
Ultra-sound guided biopsy from one of the hepatic
tumours concluded recurrence of GIST with the fol-
lowing morphological and immunohistochemical charac-
teristics: Two mitoses per 8 HPF; Ki-67 was 5 % on
average but up to 20 % in hot spots; mutation in KIT exon
9 but no mutations in PDGFRA Exon 18.
The hypercalcemia was initially treated with intravenous
saline and 600 IU of calcitonin and the day after oral pred-
nisolone 37.5 mg/day was initiated. P-ionized calcium ini-
tially decreased to 1.71 mmol/L but on day four increased
again to 2.17 mmol/L and another dose of calcitonin was
administered. The results of the p-25-hydroxy vitamin D
analyses appeared on day five and as expected, 25-OH
Vitamin D2 was unmeasurable and 25-hydroxy vitamin D3
normal (81 nmol/L). Hence, as the risk of bisphosphonate-
induced hypocalcemia was thought to be minimal, intra-
venous zoledronic acid (4 mg) was administered (Fig. 1).
The patient was discharged on day 7 with the recom-
mendation of increased oral fluid intake.
Oral imatinib therapy started on day 10 at the oncology
department, and the patient was followed up by regular
controls. Plasma level of ionized calcium was normalized
on day 16 and prednisolone was tapered off and ultima-
tively stopped on day 33. There were no adverse or
unanticipated events related to the treatment.
Two weeks after initiation of imatinib, p-calcitriol had
decreased to 224 pmol/L. A follow-up CT scan eight weeks
after the first showed a significant reduction in tumour size.
Imatinib was continued and after 15 weeks of treatment
p-calcitriol was nearly normalized at 181 pmol/L. P-
ionized calcium remained in the reference interval.
Discussion
Various vitamin D molecules (calciferols) exist, the two
of principal importance being vitamin D3 and Vitamin
Table 1 Blood analyses






















Creatininium 45–90 mikromol/L 59 123 108 95 99 93 82 83 82 67 62
Calcium (ion) 1.18–1.32 mmol/L - 2.11 1.71 1.82 2.17 1.74 1.60 1.61 1.29 - 1.29
Alkaline
phosphatise
35–105 U/L 101 148 - - - 127 - 100 132
PTH 1.6–6.9 pmol/L 6.1 1.5 - - - - - 6.3 3.3
PTHrP <2.6 pmol/L - - - - - <1.9 - - -
D2 (25-OH
Vitamin D2)
<10 <10 - - - - - - <10
D3 (25-OH
Vitamin D3)
78 81 - - - - - - 117
Calcitriol (1,25
(OH)2 vitamin D3)
60–180 pmol/L - 375 - - - - - 224 181
Values outside the local reference range are shown in bold
Plasma levels of sodium, potassium, magnesium, and TSH were normal at all timepoints
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D2. The major source of vitamin D is dermal synthesis of
Vitamin D3, cholecalciferol, when exposed to ultraviolet
light. Vitamin D3 also occurs in food and can be taken as
a supplementary vitamin. In the non-hydroxylated form
vitamin D3 is metabolically inactive. The first step towards
activation takes place in the liver and is hydroxylation at
position 25, this is followed by hydroxylation at position 1,
which primarily takes place in the kidneys and is mediated
by the enzyme 1α-hydroxylase. The activated vitamin D;
1,25-dihydroxy-vitamin D3 (=1,25-OH vitamin D3) is also
called calcitriol [5].
Vitamin D2, ergocalciferol, (produced by some fungi)
is of minor importance in humans if not consumed as a
vitamin supplement. Figure 2 shows the synthesis of
active vitamin D.
Both monohydroxylated vitamin D and dihydroxylated
vitamin D bind to the vitamin D receptor (VDR) in the
small intestines, kidneys and bones, but calcitriol binds
with a much stronger affinity than the other metabolites
[6]. Stimulation of the VDRs increases intestinal absorp-
tion and renal reabsorption of calcium and promotes
mineralization of bone [7].
Most cases of TIH are caused by either HHM or
osteolytic bone metastasis. In this patient, alkaline phos-
phatase was elevated but the patient was found to be
without bone metastasis. HHM was dismissed by a nega-
tive blood test for PTHrP, and hyperparathyrodism from
ectopic PTH production, a rare cause of hypercalcemia
in cancer, was dismissed by decreased plasma PTH. In
some cancers including multiple myeloma, breast cancer,
prostate cancer, and renal carcinoma hypercalcemia may
be induced by production of osteoclast-activating factors
such as tumor necrosis factor alpha, interleukine 6, and
receptor activator of nuclear factor-κB ligand (RANKL)
Fig. 1 Changes in plasma-ionized calcium and estimated glomerular filtration rate (eGFR) in response to treatment. Treatment administered: intravenous
saline (day one), 600 IU of calcitonin (days one and four), 37.5 mg/day of prednisolone (day two and onwards), and 4 mg of intravenous zoledronic acid
(day five)
Fig. 2 Vitamin D synthesis. Taken from Mostafa et Hegazy [22]. Synthesis and activation of Vitamin D subtypes
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[8, 9]. In our case, however, both the PET-CT and the
absence of monoclonal protein in the blood ruled out
these cancers.
Analysis of vitamin D subtypes revealed normal levels
of both 25-OH Vitamin D2 and 25-OH Vitamin D3,
whereas 1,25 OH Vitamin D3 (calcitriol) was elevated.
Reasons for a picture with elevated calcitriol, normal
25-OH vitamin D, and minimally lowered PTH could
be treatment with calcitriol (sometimes used in the
treatment of parathyroid or kidney disease) or endogenous
production of calcitriol. The patient, however, was not
treated with calcitriol.
Extra-renal 1α-hydroxylase activity and autocrine/para-
crine secretion of calcitriol have been detected in normal
tissue (skin, breast, immune system, bone, and intestines)
although activity of the enzyme is not sufficient to elevate
calcitriol in the blood [6, 10].
Recently, most types of cancer tissue have been found
to express autocrine/paracrine 1α-hydroxylase activity but
it is not clear whether the aberrant regulation of the
vitamin D system is a consequence of the malignant trans-
formation or contributes to tumour development [11].
It is well-known that hypercalcemia caused by extra-
renal 1α-hydroxylase activity may occur in patients
suffering from lymphoma [12] and in patients with
benign granulomatous diseases such as sarcoidosis [13].
Based on the clinical picture and laboratory investigations
our patient was judged free from these diseases.
Elevated calcitriol as a stand-alone biochemical cause
of hypercalcemia has only been reported in a few patients
with solid cancers (other than lymphomas) [14–17]. Evans
et al. analysed the expression of 1α-hydroxylase in tissue
from 12 patients with dysgerminomas. They concluded
that the enzyme was expressed by both tumour cells and
macrophages associated with the tumour; the localised
produced calcitriol eventually spilled over into the circula-
tion causing hypercalcemia. The authors speculated if the
high expression of 1α-hydroxylase in the tumour is part of
the immune response [15].
In the present case, the fact that the hypercalcemia did
not respond to treatment with inhibition of osteoclast
activity by intravenous zoledronic acid, also indicates a
non-bone related mechanism of TIH. In general gluco-
corticoid therapy is expected to lower the calcium levels
within three to five days and it has previously been shown
that glucocorticoids are specifically effective when treating
calcitriol-induced hypercalcemia [18]. Hence, the insuffi-
cient response to oral glucocorticoid therapy five days
after initiation is a surprising finding which could be
caused by an insufficient oral dose of glucocorticoid. The
conclusive treatment of the hypercalcemia appeared
to be the tyrosine kinase inhibitor imatinib, which
has previously proved effective in other cases of TIH
in GIST [3, 19, 20]. One could speculate whether
treatment with tyrosine kinase inhibitors is generally
effective in critical TIH and should be tried when the
standard treatment of hypercalcemia fails.
Regarding GIST, we have found only four reports on hy-
percalcemia. In two of the cases, the reason for hypercal-
cemia was not sought [19, 21], in one case hypercalcemia
was found to be PTHrP-mediated [20], and in the last case
hypercalcemia was found to be calcitriol-mediated (not
secondary to elevated PTH or PTHrP) [3].
In our case, elevated calcitriol was the only identified rea-
son for the hypercalcemia. We believe that GIST tumour
cells or tumour-associated cells possessed 1α-hydroxylase
activity causing elevated p-calcitriol and p-ionized calcium.
Conclusions
In conclusion, hypercalcemia in a patient with GIST is a
very rare phenomenon; moreover, this is only the second
case report proposing that GIST tissue have high 1α-
hydroxylase activity which can lead to increased levels of
calcitriol and secondarily hypercalcemia. Our finding is
corroborated by the fact that oncologic treatment lead to
a reduction in tumor size with contemporary decreasing
levels of p-calcitriol. To validate this finding, we recom-
mend analysis of 1α-hydroxylase activity in GIST tissue
especially from patients presenting with hypercalcemia
and elevated calcitriol.
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